glp-1 receptor agonists should be avoided in patients with MYTH BUSTER #1 “Weight-loss injections like medicines are not safe.” Is this really true? GLP-1 (such as Ozempic®) are among the most discussed anti-obesity medicines today. Unfortunately, misinformation on Frontiers | Mechanisms of action

10.1161/CIRCRESAHA.116.305360 103 TangW

6g), along with the spleen size (Fig

450 Experimentally reducing astrocyte calcium signalling in striatal circuits induces OCD-like repetitive behaviours in rodents

This shortens reagent preparation and removes a source of variability arising from self-dissolution

Trial sequential analysis: novel approach for meta-analysis

Since then, the evolution of GLP-1 receptor agonists has progressed from initial short-duration agents like exenatide, to intermediate-duration formulations such as liraglutide, and further to advanced long-acting options including dulaglutide and semaglutide (The two products received approval for marketing in the U.S